223 related articles for article (PubMed ID: 24135850)
21. The necessity of cytoreductive nephrectomy in patients with metastatic renal cell carcinoma using antiangiogenic targeted therapy after interferon alfa-2b.
Mutlu H; Gündüz S; Büyükçelik A; Yıldız O; Uysal M; Tural D; Bozcuk H; Coşkun HŞ
Clin Genitourin Cancer; 2014 Dec; 12(6):447-50. PubMed ID: 25022784
[TBL] [Abstract][Full Text] [Related]
22. Comparative Effectiveness of Initial Surgery vs Initial Systemic Therapy for Metastatic Kidney Cancer in the Targeted Therapy Era: Analysis of a Population-based Cohort.
Macleod LC; Odisho AY; Tykodi SS; Holt SK; Harper JD; Gore JL
Urology; 2018 Mar; 113():146-152. PubMed ID: 29174942
[TBL] [Abstract][Full Text] [Related]
23. Prognostic effect of cytoreductive nephrectomy in synchronous metastatic renal cell carcinoma: a comparative study using inverse probability of treatment weighting.
Klatte T; Fife K; Welsh SJ; Sachdeva M; Armitage JN; 'Aho T; Riddick AC; Matakidou A; Eisen T; Stewart GD
World J Urol; 2018 Mar; 36(3):417-425. PubMed ID: 29256020
[TBL] [Abstract][Full Text] [Related]
24. Cytoreductive nephrectomy for metastatic RCC in the era of targeted therapy.
Abel EJ; Wood CG
Nat Rev Urol; 2009 Jul; 6(7):375-83. PubMed ID: 19528960
[TBL] [Abstract][Full Text] [Related]
25. Use of systemic therapy and factors affecting survival for patients undergoing cytoreductive nephrectomy.
Kutikov A; Uzzo RG; Caraway A; Reese CT; Egleston BL; Chen DY; Viterbo R; Greenberg RE; Wong YN; Raman JD; Boorjian SA
BJU Int; 2010 Jul; 106(2):218-23. PubMed ID: 19922542
[TBL] [Abstract][Full Text] [Related]
26. Comparative Survival Associated With Use of Targeted vs Nontargeted Therapy in Medicare Patients With Metastatic Renal Cell Carcinoma.
Li P; Jahnke J; Pettit AR; Wong YN; Doshi JA
JAMA Netw Open; 2019 Jun; 2(6):e195806. PubMed ID: 31199450
[TBL] [Abstract][Full Text] [Related]
27. Too good for CARMENA: criteria associated with long systemic therapy free intervals post cytoreductive nephrectomy for metastatic clear cell renal cell carcinoma.
Roussel E; Verbiest A; Milenkovic U; Van Cleynenbreugel B; Van Poppel H; Joniau S; Beuselinck B; Albersen M
Scand J Urol; 2020 Dec; 54(6):493-499. PubMed ID: 32924729
[TBL] [Abstract][Full Text] [Related]
28. Epidemiologic trends in renal cell carcinoma in the cytokine and post-cytokine eras: a registry analysis of 28,252 patients.
Shek D; Tomlinson B; Brown M; Brunson A; Pan CX; Lara PN
Clin Genitourin Cancer; 2012 Jun; 10(2):93-8. PubMed ID: 22382008
[TBL] [Abstract][Full Text] [Related]
29. Prognostic significance of cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma treated with first-line sunitinib: a European multiinstitutional study.
Bamias A; Tzannis K; Papatsoris A; Oudard S; Beuselinck B; Escudier B; Liontos M; Elaidi TR; Chrisofos M; Stravodimos K; Anastasiou I; Mitropoulos D; Deliveliotis C; Constantinides C; Dimopoulos MA; Bamia C
Clin Genitourin Cancer; 2014 Oct; 12(5):373-83. PubMed ID: 24819319
[TBL] [Abstract][Full Text] [Related]
30. External validation of a predictive model of survival after cytoreductive nephrectomy for metastatic renal cell carcinoma.
Marconi L; de Bruijn R; van Werkhoven E; Beisland C; Fife K; Heidenreich A; Kapoor A; Karam J; Kauffmann C; Klatte T; Ljungberg B; Matin S; Sjoberg D; Staehler M; Stewart GD; Tanguay S; Uzzo R; Welsh S; Wood L; Wood C; Bex A
World J Urol; 2018 Dec; 36(12):1973-1980. PubMed ID: 30069581
[TBL] [Abstract][Full Text] [Related]
31. The Role of Nephrectomy for Kidney Cancer in the Era of Targeted and Immune Therapies.
Vaishampayan UN
Am Soc Clin Oncol Educ Book; 2016; 35():e16-20. PubMed ID: 27249719
[TBL] [Abstract][Full Text] [Related]
32. Cytoreductive nephrectomy: past, present and future.
Galazi M; Rodriguez-Vida A; Josephides E; Chau NM; Chowdhury S
Expert Rev Anticancer Ther; 2014 Mar; 14(3):271-7. PubMed ID: 24392671
[TBL] [Abstract][Full Text] [Related]
33. Survival among patients with advanced renal cell carcinoma in the pretargeted versus targeted therapy eras.
Li P; Wong YN; Armstrong K; Haas N; Subedi P; Davis-Cerone M; Doshi JA
Cancer Med; 2016 Feb; 5(2):169-81. PubMed ID: 26645975
[TBL] [Abstract][Full Text] [Related]
34. The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer.
Powles T; Blank C; Chowdhury S; Horenblas S; Peters J; Shamash J; Sarwar N; Boleti E; Sahdev A; O'Brien T; Berney D; Beltran L; Nathan P; Haanen J; Bex A
Eur Urol; 2011 Sep; 60(3):448-54. PubMed ID: 21612860
[TBL] [Abstract][Full Text] [Related]
35. Survival advantage of upfront cytoreductive nephrectomy in patients with primary metastatic renal cell carcinoma compared with systemic and palliative treatments in a real-world setting.
Ljungberg B; Sundqvist P; Lindblad P; Kjellman A; Thorstenson A; Hellström M; Kröger Dahlin BI; Thomasson M; Harmenberg U; Lundstam S
Scand J Urol; 2020 Dec; 54(6):487-492. PubMed ID: 32897123
[TBL] [Abstract][Full Text] [Related]
36. Significance of upfront cytoreductive nephrectomy stratified by IMDC risk for metastatic renal cell carcinoma in targeted therapy era - a multi-institutional retrospective study.
Kato R; Naito S; Numakura K; Hatakeyama S; Koguchi T; Kojima T; Kawasaki Y; Kandori S; Kawamura S; Arai Y; Ito A; Nishiyama H; Kojima Y; Ohyama C; Habuchi T; Tsuchiya N; Obara W
Int J Clin Oncol; 2022 Mar; 27(3):563-573. PubMed ID: 34973106
[TBL] [Abstract][Full Text] [Related]
37. Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma.
Bhindi B; Abel EJ; Albiges L; Bensalah K; Boorjian SA; Daneshmand S; Karam JA; Mason RJ; Powles T; Bex A
Eur Urol; 2019 Jan; 75(1):111-128. PubMed ID: 30467042
[TBL] [Abstract][Full Text] [Related]
38. Comparative Survival following Initial Cytoreductive Nephrectomy versus Initial Targeted Therapy for Metastatic Renal Cell Carcinoma.
Bhindi B; Habermann EB; Mason RJ; Costello BA; Pagliaro LC; Thompson RH; Leibovich BC; Boorjian SA
J Urol; 2018 Sep; 200(3):528-534. PubMed ID: 29574109
[TBL] [Abstract][Full Text] [Related]
39. Cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy in the United States: a SEER analysis.
Tsao CK; Small AC; Kates M; Moshier EL; Wisnivesky JP; Gartrell BA; Sonpavde G; Godbold JH; Palese MA; Hall SJ; Oh WK; Galsky MD
World J Urol; 2013 Dec; 31(6):1535-9. PubMed ID: 23223962
[TBL] [Abstract][Full Text] [Related]
40. Safety of presurgical targeted therapy in the setting of metastatic renal cell carcinoma.
Chapin BF; Delacroix SE; Culp SH; Nogueras Gonzalez GM; Tannir NM; Jonasch E; Tamboli P; Wood CG
Eur Urol; 2011 Nov; 60(5):964-71. PubMed ID: 21621907
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
